Alpha-Synuclein (alphaSyn or SNCA) - Pipeline Review, H1 2016

  • ID: 3802792
  • Drug Pipelines
  • 84 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AC Immune SA
  • AFFiRiS AG
  • BioArctic Neuroscience AB
  • Biogen, Inc.
  • Neuropore Therapies, Inc.
  • nLife Therapeutics, S.L.
  • MORE
Alpha-Synuclein (alphaSyn or SNCA) - Pipeline Review, H1 2016

Summary

‘Alpha-Synuclein (alphaSyn or SNCA) - Pipeline Review, H1 2016’, provides in depth analysis on Alpha-Synuclein (alphaSyn or SNCA) targeted pipeline therapeutics.

The report provides comprehensive information on the Alpha-Synuclein (alphaSyn or SNCA), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Alpha-Synuclein (alphaSyn or SNCA)
- The report reviews Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics and enlists all their major and minor projects
- The report assesses Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Alpha-Synuclein (alphaSyn or SNCA)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alpha-Synuclein (alphaSyn or SNCA) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AC Immune SA
  • AFFiRiS AG
  • BioArctic Neuroscience AB
  • Biogen, Inc.
  • Neuropore Therapies, Inc.
  • nLife Therapeutics, S.L.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Alpha-Synuclein (alphaSyn or SNCA) Overview

Therapeutics Development

Alpha-Synuclein (alphaSyn or SNCA) - Products under Development by Stage of Development

Alpha-Synuclein (alphaSyn or SNCA) - Products under Development by Therapy Area

Alpha-Synuclein (alphaSyn or SNCA) - Products under Development by Indication

Alpha-Synuclein (alphaSyn or SNCA) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Alpha-Synuclein (alphaSyn or SNCA) - Products under Development by Companies

Alpha-Synuclein (alphaSyn or SNCA) - Products under Development by Universities/Institutes

Alpha-Synuclein (alphaSyn or SNCA) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Alpha-Synuclein (alphaSyn or SNCA) - Companies Involved in Therapeutics Development

AC Immune SA

AFFiRiS AG

BioArctic Neuroscience AB

Biogen, Inc.

NeuroPhage Pharmaceuticals, Inc.

Neuropore Therapies, Inc.

nLife Therapeutics, S.L.

Primary Peptides, Inc.

Prothena Corporation Plc

QR Pharma, Inc.

reMYND NV

Synovo GmbH

Alpha-Synuclein (alphaSyn or SNCA) - Drug Profiles

BAN-0805 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIIB-054 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLR-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DPC-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Kenterin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Tau, Amyloid Beta and Alpha-Synuclein for Neurodegenerative Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NLFPD-1233 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPT-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPT-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPT-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPT-088 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPT-133 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPT-20011 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPT-3G - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PD-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PD-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PD-04 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Posiphen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PP-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRX-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

quinpramine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ReS-12S - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ReS-9S - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Alpha-Synuclein and Lcn2 for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trehalose - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Alpha-Synuclein for Neurodegenerative Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Alpha-Synuclein for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Alpha-Synuclein (alphaSyn or SNCA) - Dormant Projects

Alpha-Synuclein (alphaSyn or SNCA) - Featured News & Press Releases

Mar 22, 2016: Neuropore Announces Successful Completion of Phase I with its Lead Compound NPT200-11

Aug 12, 2015: Neuropore Therapies Commences Phase 1 Clinical Trials

Jul 19, 2015: NeuroPhage's NPT088 Universally Targets Misfolded Proteins in Preclinical Studies Highlighted in Oral Session at the Alzheimer's Association International Conference

Jul 13, 2015: NeuroPhage to be Featured in Oral Session at the 2015 Alzheimer’s Association International Conference

Jul 02, 2015: BIIB054 reached significant milestone

Jun 17, 2015: Prothena Presents Clinical Results Demonstrating Robust, Rapid Reduction in Levels of Free Serum Alpha-Synuclein of Up to 96% After Single Dose of PRX002, Novel Protein Immunotherapy for Parkinson's Disease

Jun 15, 2015: BioArctic Neuroscience Parkinson’s disease program receives grant from VINNOVA

Jun 08, 2015: Prothena to Present Clinical Results From Its Phase 1 Single Ascending Dose Study of PRX002 at 19th International Congress of Parkinson's Disease and Movement Disorders

Apr 02, 2015: 2nd US patent granted on therapeutic antibodies for Parkinson’s disease

Mar 19, 2015: Prothena Reports Robust Reduction of Free Serum Alpha-Synuclein of up to 96% After Single Dose of PRX002, a Novel Protein Immunotherapy for Parkinson's Disease

Mar 16, 2015: NeuroPhage to Present at 12th International Conference on Alzheimer’s & Parkinson’s Diseases

Dec 09, 2014: Parkinson's Vaccine: EU-Team Launches Clinical Trial Vaccine candidate based on proprietary technology by AFFiRiS

Nov 14, 2014: NeuroPhage’s GAIM Technology Chosen As Top Project To Watch For The Therapeutic Area Partnerships Conference

Aug 26, 2014: Prothena Announces Presentation at Federation of European Physiological Societies 2014 Congress

Jul 31, 2014: First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 84List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by AC Immune SA, H1 2016

Pipeline by AFFiRiS AG, H1 2016

Pipeline by BioArctic Neuroscience AB, H1 2016

Pipeline by Biogen, Inc., H1 2016

Pipeline by NeuroPhage Pharmaceuticals, Inc., H1 2016

Pipeline by Neuropore Therapies, Inc., H1 2016

Pipeline by nLife Therapeutics, S.L., H1 2016

Pipeline by Primary Peptides, Inc., H1 2016

Pipeline by Prothena Corporation Plc, H1 2016

Pipeline by QR Pharma, Inc., H1 2016

Pipeline by reMYND NV, H1 2016

Pipeline by Synovo GmbH, H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016 73List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AC Immune SA
  • AFFiRiS AG
  • BioArctic Neuroscience AB
  • Biogen, Inc.
  • Neuropore Therapies, Inc.
  • nLife Therapeutics, S.L.
  • MORE
Alpha-Synuclein (alphaSyn or SNCA) Alpha-synuclein is a protein normally found in cells all over the body. It is one of the key players in Parkinson’s. In Parkinson’s it forms clumps inside the specific nerve cells that produce the chemical dopamine. It is involved in the regulation of dopamine release and transport. It induces fibrillization of microtubule-associated protein tau. It reduces neuronal responsiveness to various apoptotic stimuli, leading to decreased caspase-3 activation.

Alpha-Synuclein (alphaSyn or SNCA) pipeline Target constitutes close to 29 molecules. Out of which approximately 24 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 13 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

The author's latest report Alpha-Synuclein - Pipeline Review, H1 2016, outlays comprehensive information on the Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 5
AC Immune SA
AFFiRiS AG
BioArctic Neuroscience AB
Biogen, Inc.
NeuroPhage Pharmaceuticals, Inc.
Neuropore Therapies, Inc.
nLife Therapeutics, S.L.
Primary Peptides, Inc.
Prothena Corporation Plc
QR Pharma, Inc.
reMYND NV
Synovo GmbH
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll